Hyperlipidemia, dyslipoproteinemia and apolipoproteinopathia--classification and risk of atherosclerosis. Part 3: Hypertriacylglycerolemia.

Hyperlipidemia, dyslipoproteinemia and apolipoproteinopathia--classification and risk of atherosclerosis. Part 3: Hypertriacylglycerolemia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Hyperlipidemia, dyslipoproteinemia and apolipoproteinopathia--classification and risk of atherosclerosis. Part 3: Hypertriacylglycerolemia. Abstract Text:

B Choluj,T Votruba,

The authors classify hypertriacylglycerolemias according to their relationship with atherosclerosis as disorders with and without chylomicronemia, atherogenous disorders with an increased level of apolipoprotein B in the VLDL fraction, and relatively harmless (benign) cases. They single out the remarkable heterogeneity of hypertriacylglycerolemias and their epidemiological aspects. The analysis of the various disorders comes complete with their pathobiochemistry and the clinic-biochemical criteria of their classification. The paper also draws attention to a number of possible clinical complications accompanying hypertriacylglycerolemias and their frequency among the population.

Hyperlipidemia, dyslipoproteinemia and apolipoproteinopathia--classification and risk of atherosclerosis. Part 3: Hypertriacylglycerolemia. Publishing Authors By Initials

B Choluj,T Votruba,

For similar investigative techniques: epidemiologic methods: statistics as topic: probability: risk: risk factors research abstracts see: investigative techniques: epidemiologic methods: statistics as topic: probability: risk: risk factors research

PUBMED ID PMID:

MEDLINE DATE:

Hyperlipidemia, dyslipoproteinemia and apolipoproteinopathia--classification and risk of atherosclerosis. Part 3: Hypertriacylglycerolemia. Journal Published:

PUBLICATION TYPE: Review

Journal: Acta Universitatis Carolinae. Medica

VOLUME: 37

Page Numbers: 116-28

Journal Abbreviation:

ISSN: 0001-7116

DAY: 20

MONTH: 02

YEAR: 1991

Hyperlipidemia, dyslipoproteinemia and apolipoproteinopathia--classification and risk of atherosclerosis. Part 3: Hypertriacylglycerolemia. Information

Number of References: 22

LANGUAGE: eng

NlmUniqueID: 2985169

Hyperlipidemia, dyslipoproteinemia and apolipoproteinopathia--classification and risk of atherosclerosis. Part 3: Hypertriacylglycerolemia. Keywords Mesh Terms:

KEYWORDS: Risk Factors

MESH TERMS: complications

Chemical & Substance for Abstract: Hyperlipidemia, dyslipoproteinemia and apolipoproteinopathia--classification and risk of atherosclerosis. Part 3: Hypertriacylglycerolemia. Information

Substance Name: Chylomicrons

Registry Number: 0

Grant and Affiliation Information for Hyperlipidemia, dyslipoproteinemia and apolipoproteinopathia--classification and risk of atherosclerosis. Part 3: Hypertriacylglycerolemia.

AFFILIATION: Department of Clinical Biochemistry, Central Military Hospital, Prague, Czechoslovakia.

Country: CZECHOSLOVAKIA

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Acta Univ Carol [Med] (Praha)

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Hyperlipidemia, dyslipoproteinemia and apolipoproteinopathia--classification and risk of atherosclerosis Part 3: Hypertriacylglycerolemia Related Publications

• A missense mutation in the murine Opa3 gene models human Costeff syndrome.
• An "overtrained" ophthalmologist responds.
• Experience with evaluation of knowledge in technical disciplines.
• Hyperlipidemia, dyslipoproteinemia and apolipoproteinopathia--classification and risk of atherosclerosis. Part 2: Hypercholesterolemia.
• Hyperlipidemia, dyslipoproteinemia and apolipoproteinopathia--classification and risk of atherosclerosis. Part 3: Hypertriacylglycerolemia.
• Hyperlipidemia, dyslipoproteinemia and apolipoproteinopathia--classification and risk of atherosclerosis. Part 4: Apolipoproteinopathia.
• Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate.
• Pyrimidine acyclic nucleoside phosphonates and phosphorylated analogs (part 2): syntheses and investigation of their inhibitory effects towards human thymidine phosphorylase.
• Systems analysis of the culture physiology in acetone-butanol fermentation.
• Thymoxamine in the treatment of traumatic mydriasis.